12:35 , May 8, 2019 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: April 2019

New Therapeutic Targets and Biomarkers: April 2019 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during April. Therapeutic targets are defined as any protein, gene or other molecule...
13:53 , Apr 10, 2019 |  BC Innovations  |  Distillery Therapeutics

Inhibiting bacterial RelA to enhance isoniazid sensitivity in tuberculosis

DISEASE CATEGORY: Infectious disease INDICATION: Tuberculosis Cell culture and mouse studies suggest inhibiting M. tuberculosis RelA could help treat chronic-phase tuberculosis (TB), which is resistant to the generic antimalarial isoniazid. In an M. tuberculosis culture-based...
19:12 , Mar 4, 2019 |  BC Innovations  |  Distillery Therapeutics

Inhibiting soluble epoxide hydrolase for renal damage

DISEASE CATEGORY: Renal INDICATION: Renal damage Mouse studies suggest inhibiting soluble epoxide hydrolase could help treat renal damage. In a mouse model of diet-induced renal injury, a soluble epoxide hydrolase inhibitor tool compound decreased renal...
04:47 , Nov 9, 2018 |  BC Innovations  |  Tools & Techniques

HitGen’s DNA for small molecules

With more than 60 partnerships under its belt, HitGen Ltd. has become a major gateway for companies to access DNA-encoded library technology -- a high efficiency form of combinatorial chemistry that upstages high throughput screening....
22:59 , Oct 11, 2018 |  BC Innovations  |  Distillery Therapeutics

Endocrine/metabolic

INDICATION: Metabolic Mouse studies suggest base editing-mediated knockout of HPD could help treat tyrosinemia type I, which is caused by mutations in FAH downstream of HPD. In an in utero mouse model of the disease...
00:00 , Aug 11, 2018 |  BioCentury  |  Product Development

Exacerbation management

Based on work spearheaded by the Cystic Fibrosis Foundation, Corbus Pharmaceuticals Holdings Inc. will be the first company to attempt to gain approval in CF based on pulmonary exacerbations instead of FEV1. The company is...
17:15 , Aug 3, 2018 |  BC Week In Review  |  Clinical News

Celtaxsys planning Phase III program for CF candidate

Celtaxsys Inc. (Atlanta, Ga.) said it hopes to start Phase III testing in 2H19 evaluating acebilustat (CTX-4430) to treat cystic fibrosis after reporting data from the Phase II EMPIRE-CF trial of the candidate in the...
16:36 , Aug 3, 2018 |  BC Week In Review  |  Clinical News

Banyan reports 97.6% sensitivity for TBI diagnostic

Banyan Biomarkers Inc. (Alachua, Fl.) said data from the ALERT-TBI study showed that its blood-based diagnostic Banyan BTI had 97.6% sensitivity and a 99.6% negative predictive value (NPV) for detecting intracranial injury to rule out...
22:15 , Aug 2, 2018 |  BC Innovations  |  Tools & Techniques

Model firsts

By combining disparate data into coherent mechanistic models, quantitative systems pharmacology is becoming a key tool for picking the right dose for first-in-human trials and other early make-or-break decisions. Advocates see it as part of...
12:01 , Aug 2, 2018 |  BC Extra  |  Clinical News

Celtaxsys planning Phase III program for CF candidate

Celtaxsys Inc. (Atlanta, Ga.) said it hopes to start Phase III testing in 2H19 evaluating acebilustat (CTX-4430) to treat cystic fibrosis after reporting data from the Phase II EMPIRE-CF trial of the candidate in the...